title: [Lung development and mesenchymal stem cells].
abstract: The survival of extremely premature newborns has increased because of improvements in perinatal care. These infants however, are at high risk for chronic lung disease of prematurity or bronchopulmonary dysplasia (BPD). BPD, the most common complication in infants born before 28 weeks of gestation, is a multifactorial disease characterized by an arrest in alveolar development. Current preventive and curative therapies show limited efficacy. Cell-based therapies hold tremendous promise in regenerative medicine. Recent evidence suggests the therapeutic benefit of mesenchymal stem (or stromal) cells (MSC) in various diseases, including among others neurodegenerative, cardiovascular and respiratory disorders. Moreover, in an oxygen-induced BPD model, we and others recently demonstrated that bone marrow (BM) derived-MSCs efficiently prevent the arrest in lung development. In this review, we summarize the current knowledge regarding the therapeutic properties and mechanisms of action, specifically paracrine, of MSCs.
authors.affiliation: Service de Réanimation, Soins Intensifs et Médecine Néonatals, 10 Rue du Dr Heydenreich, 54042 Nancy cedex, France. bthebaud@ualberta.ca
authors.forename: P
authors.initials: P
authors.lastname: Waszak
authors.forename: B
authors.initials: B
authors.lastname: Thébaud
mesh_terms: D001854:Bone Marrow Cells / Q000166:cytology; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D008168:Lung / Q000254:growth & development; D008171:Lung Diseases / Q000628:therapy*; D045164:Mesenchymal Stem Cell Transplantation; D012038:Regeneration